background
spite
global
contain
prevent
effort
spread
coronaviru
diseas
continu
rise
million
confirm
case
death
record
worldwid
sinc
april
outbreak
signific
threat
intern
health
economi
present
approv
vaccin
treatment
diseas
effort
underway
remdesivir
nucleotideanalogu
antivir
drug
develop
ebola
determin
prevent
stop
infect
result
yet
controversi
aim
conduct
systemat
review
metaanalysi
random
control
trial
compar
effect
remdesivir
placebo
patient
covid
method
analysi
search
medlinepubm
embas
cochran
librari
clinicaltrialsgov
googl
scholar
databas
without
restrict
year
public
includ
random
control
trial
assess
effect
remdesivir
versu
placebo
patient
confirm
follow
prefer
report
item
systemat
review
metaanalysi
prisma
guidelin
design
report
result
primari
endpoint
time
clinic
recoveri
secondari
endpoint
caus
mortal
discharg
date
frequenc
respiratori
progress
treatmentemerg
advers
event
two
independ
author
perform
studi
select
data
extract
methodolog
qualiti
assess
revman
softwar
use
statist
analysi
randomfix
effect
model
carri
calcul
mean
differ
continu
outcom
risk
ratio
dichotom
outcom
remdesivir
placebo
studi
requir
ethic
approv
particip
data
involv
systemat
review
metaanalysi
find
studi
publish
reput
peerreview
journal
registr
review
protocol
submit
prospero
databas
registr
includ
registr
number
revis
version
manuscript
systemat
review
metaanalysi
deriv
random
control
trial
increas
qualiti
evid
systemat
review
metaanalysi
deriv
random
control
trial
reduc
studi
heterogen
subgroup
sensit
analysi
carri
identifi
possibl
reason
may
caus
signific
heterogen
studi
use
cochran
risk
bia
tool
assess
risk
bia
includ
studi
extract
synthes
evid
base
conclus
one
limit
studi
might
restrict
trial
publish
english
languag
cours
decemb
health
author
wuhan
citi
hubei
provinc
china
report
cluster
pneumonia
case
unknown
etiolog
chines
research
rapidli
isol
sever
acut
respiratori
syndrom
coronaviru
patient
januari
came
genom
sequenc
januari
china
communic
diseas
control
author
announc
novel
coronaviru
detect
caus
agent
epidem
spite
global
contain
prevent
effort
spread
continu
rise
million
confirm
case
death
record
worldwid
sinc
april
outbreak
infect
signific
threat
intern
health
economi
present
approv
vaccin
treatment
identifi
drug
treatment
option
soon
possibl
critic
agenda
overcom
outbreak
despit
lack
approv
drug
vaccin
mani
scientist
endeavor
find
medicin
specif
viru
look
repurpos
alreadi
approv
drug
march
clinic
trial
regist
clinicaltrialsgov
estim
current
sever
drug
remdesivir
hydroxychloroquin
chloroquin
ritonavirlopinavir
arbidol
interferon
undergo
random
control
trial
rct
test
efficaci
safeti
treatment
mani
countri
among
investig
drug
remdesivir
show
promis
result
remdesivir
nucleotid
analog
prodrug
show
broad
spectrum
antivir
activ
mani
rna
virus
includ
remdesivir
report
treatment
unit
state
china
itali
result
yet
controversi
bridg
gap
aim
conduct
systemat
review
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
metaanalysi
rct
compar
effect
remdesivir
placebo
patient
protocol
systemat
review
metaanalysi
submit
prospero
databas
registr
includ
registr
number
revis
version
manuscript
search
medlinepubm
http
wwwncbinlmnihgovpubm
embas
remdesivir
nucleotideanalogu
antivir
drug
random
control
trial
potenti
elig
studi
consid
review
irrespect
primari
outcom
manual
search
perform
find
addit
elig
trial
refer
list
key
articl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
studi
elig
criteria
systemat
review
metaanalysi
accord
particip
intervent
comparison
outcom
studi
design
pico
descript
popul
popul
patient
confirm
without
comorbid
condit
age
group
intervent
experiment
group
dose
remdesivir
compar
group
placebo
standard
care
primari
endpoint
time
clinic
recoveri
proport
particip
reliev
clinic
symptom
defin
time
hour
initi
studi
treatment
secondari
endpoint
caus
mortal
discharg
date
frequenc
respiratori
progress
oxygen
satur
treatmentemerg
advers
event
group
rct
evalu
effect
remdesivir
versu
placebo
patient
includ
titl
abstract
search
studi
examin
two
independ
review
author
titl
abstract
studi
identifi
databas
search
studi
duplic
meet
elig
criteria
exclud
full
text
remain
studi
review
disagr
resolv
consensu
persist
arbitr
discuss
third
review
author
follow
prefer
report
item
systemat
review
metaanalysi
prisma
guidelin
design
report
result
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
two
author
independ
extract
data
accord
predesign
data
extract
tool
follow
data
extract
includ
rct
first
author
year
public
fund
inform
set
mean
age
particip
intervent
compar
dose
number
particip
random
durat
treatment
primari
secondari
outcom
measur
disagr
regard
data
extract
two
er
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
review
author
exist
third
author
consult
consensu
made
discuss
cochran
risk
bia
tool
use
assess
risk
bia
includ
studi
risk
bia
trial
judg
two
independ
review
author
low
unclear
high
base
critic
domain
includ
random
sequenc
gener
alloc
conceal
blind
incomplet
outcom
data
select
report
sourc
bias
disagr
resolv
discuss
among
author
disagr
resolv
discuss
arbit
make
final
decis
metaanalysi
carri
use
comput
softwar
packag
revman
continu
outcom
data
report
use
mean
differ
md
confid
interv
ci
binari
outcom
data
summar
use
risk
ratio
rr
ci
mantelhaenszel
method
use
pool
effect
estim
dichotom
outcom
invers
varianc
continu
outcom
cochran
q
test
use
assess
heterogen
studi
test
done
quantifi
heterogen
studi
valu
repres
moderatetohigh
heterogen
heterogen
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
accept
fixedeffect
model
use
pool
data
hand
unaccept
heterogen
detect
number
studi
small
randomeffect
model
use
pool
data
subgroup
analysi
carri
identifi
possibl
reason
may
caus
signific
heterogen
studi
get
accept
heterogen
subgroup
analysi
perform
metaanalysi
otherwis
narr
descript
sensit
analysi
conduct
see
robust
pool
data
remov
low
qualiti
studi
statist
analysi
pvalu
consid
statist
signific
individu
particip
data
initi
unavail
review
origin
sourc
andor
publish
trial
report
contact
author
obtain
clarif
data
conduct
funnel
plot
egger
test
check
possibl
report
bia
suffici
number
includ
studi
least
trial
avail
studi
studi
requir
ethic
approv
particip
data
involv
systemat
review
metaanalysi
find
studi
publish
reput
peerreview
journal
